Navigation Links
Signum Biosciences, Inc. Announces Collaborative Agreement with GlaxoSmithKline
Date:11/10/2011

PRINCETON, N.J., Nov. 10, 2011 /PRNewswire/ -- Signum Biosciences, Inc., a privately held biotechnology company, has entered into an agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).

The agreement provides Signum with research support and milestone payments.  GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and development activities in neurosciences.

GSK and Signum will undertake a broad R&D collaboration to screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation.  Signum's partnership with GSK furthers Signum's position as an innovative biotech company, advancing pioneering drug discovery and leveraging GSK's capabilities in research and development.

Maxwell Stock, President of Signum Biosciences, commented, "GSK is an ideal partner for Signum.  We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies.  We are proud to be working in collaboration with a leading pharmaceutical company in innovative research and development.  Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug."  

About Signum Biosciences, Inc.

Signum, a Princeton, New Jersey- based biotechnology company, dedicated to developing small-molecule therapeutics derived from its Phosphatase platform to modulate signal transduction imbalances.  Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer's, Parkinson's and other neurodegenerative diseases.  Signum's technology provid
'/>"/>

SOURCE Signum Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
4. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
5. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
6. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
7. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
8. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
9. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
11. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  A prospective study ... Sweden has validated the performance of ... and has associated volumetrically assessed breast density measurements ... Epidemiology, Biomarkers & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the ... tool for widespread breast cancer risk assessment," was ...
(Date:7/28/2014)... , July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... company, announced today that its new PicoWay® device has ... types and colors and pigmented lesions on any skin ... device, with 532nm and 1064nm wavelengths, which utilizes Syneron,s ... using pulses which are trillionths of a second, known ...
(Date:7/28/2014)... MONACO , 28 luglio 2014 ResMed ... sviluppo di prodotti per la cura dei disturbi respiratori ... respiratorio, ha avuto un,ingiunzione permanente in Germania contro il ... che proibisce la vendita di apparecchiature da indossare in ... 210 e le maschere 220. La sentenza della Corte ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2
... Diagnostics, Gene Expression Test Is the First to Receive FDA, ... ... Cancer Cases Annually, SUNNYVALE, Calif., July 31 Pathwork Diagnostics, ... Food and Drug Administration (FDA) has cleared its Pathwork(R),Tissue of Origin ...
... 31 Oramed Pharmaceuticals,Inc. (OTCBB: ORMP) ( http://www.oramed.com ), ... will hold a conference call on August 6,2008 at ... Phase 2A clinical trials,of its flagship product, ORMD 0801, ... is focused on assessing the safety and efficacy,of ORMD ...
Cached Medicine Technology:FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 2FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 3FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 4Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials 2
(Date:7/28/2014)... a surgical procedure to treat severe chronic migraine headaches ... of the time in patients treated at Massachusetts General ... Plastic and Reconstructive Surgery report that more than half ... all of whom had headaches associated with compression of ... later. The team,s paper has received advance online ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... filed on behalf of individuals who were allegedly ... Replacement System continue to move forward in U.S. District ... According to an Order issued on July 18, 2014, ... a motion filed by the Plaintiffs’ Steering Committee that ...
(Date:7/28/2014)... 2014 Glutamine is the most abundant ... to be conditionally essential during times when the body ... recovery & Immune System Support. , Having a heavy ... produces, supplementing with additional glutamine may be advantageous. Glutamine ... the body, digestion and immune system function. Stress on ...
(Date:7/28/2014)... July 28, 2014 Ticket Down ... tickets in Miami, FL at the Sun Life Stadium ... American football between Argentina and Brazil has is one that ... worldwide, more rivalries are forming on a consistent basis. ... a new height in the recent 2014 World Cup. ...
(Date:7/28/2014)... chronic medical conditions people have at retirement age, the ... claims. Since nearly four in five older ... Bloomberg School of Public Health in Baltimore said the ... are slowing in the United States. "Living with ... heart failure is now the norm and not the ...
Breaking Medicine News(10 mins):Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2
... Dr. Bijan Afar, a well-respected ... Many California residents are now able to benefit from the competent care of Dr. Afar and ... ... to announce the opening of his new office location in North Hollywood. All of the benefits ...
... ... Through Managing Electricity , ... Plano, TX (PRWEB) June 22, 2010 -- Vedero Software, a leading provider ... company Smart Energy Cloud. Under terms of the partnership agreement, Smart Energy Cloud ...
... tendencies until early adulthood, study finds , TUESDAY, June ... outlook are less likely to abuse alcohol, even if they ... Being religious does not, however, appear to prevent such abuse ... are reported in the September issue of Alcoholism: Clinical ...
... ... online medical image cloud computing service, today announced the following organizations will use ... ... June 22, 2010 -- SeeMyRadiology.com ( http://www.SeeMyRadiology.com ), Accelarad’s online medical ...
... ... line of “Eastern” products that address major physiological issues like sleep deprivation, stress, immune ... company,s supplements, oils and creams are comprised of a unique blend of natural ingredients ... ...
... the problem had higher levels of BPA, but study ... (HealthDay News) -- There may be more troubling news ... with polycystic ovary syndrome have higher levels of the ... ovaries of women with polycystic ovary syndrome (PCOS) develop ...
Cached Medicine News:Health News:Trusted Los Angeles Dentist, Dr. Bijan Afar, is Now Practicing in Hollywood Area 2Health News:Trusted Los Angeles Dentist, Dr. Bijan Afar, is Now Practicing in Hollywood Area 3Health News:Vedero Software Announces Partnership with Smart Energy Cloud for Automated Demand Response 2Health News:Vedero Software Announces Partnership with Smart Energy Cloud for Automated Demand Response 3Health News:Accelarad Announces Six New SeeMyRadiology.com Customers Seeking Fast, Secure and Innovative Medical Image Exchange Solution 2Health News:Launching Today: Herbal Destination, a New Kind of Company for Herbal Supplements, Oils and Creams 2Health News:Plastics Chemical BPA May Be Tied to Ovarian Cysts 2Health News:Plastics Chemical BPA May Be Tied to Ovarian Cysts 3
... The NMP22 BladderChek Test is the only in-office ... of bladder cancer. The NMP22 BladderChek Test is ... single urine sample, that detects elevated levels of ... amounts of NMP22 protein in the urine. However, ...
... Kit is a quantitative microplate enzyme immunoassay that ... generally have very small amounts of NMP22 protein ... protein is often elevated in the urine of ... of the disease. The use of the NMP22 ...
... and urethral pressure profilometry. The catheter's ... to be filled while cystometry is ... catheter in the bladder for urodynamic ... standing or sitting. Supplied sterile in ...
... urethral pressure profilometry. Single lumen catheter ... the bladder and more accurate cystometric ... allows the bladder to be filled ... catheter construction allows cystometry and urethral ...
Medicine Products: